Literature DB >> 29782561

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

Francesco Facchinetti1, Luc Friboulet2.   

Abstract

Entities:  

Year:  2018        PMID： 29782561      PMCID： PMC5943229          DOI： 10.21037/tlcr.2018.02.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

3.  Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Authors:  Francesco Facchinetti; Yohann Loriot; Mei-Shiue Kuo; Linda Mahjoubi; Ludovic Lacroix; David Planchard; Benjamin Besse; Françoise Farace; Nathalie Auger; Jordi Remon; Jean-Yves Scoazec; Fabrice André; Jean-Charles Soria; Luc Friboulet
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

Review 4.  Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.

Authors:  Francesco Facchinetti; Giulio Rossi; Emilio Bria; Jean-Charles Soria; Benjamin Besse; Roberta Minari; Luc Friboulet; Marcello Tiseo
Journal:  Cancer Treat Rev       Date:  2017-03-12       Impact factor: 12.111

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

6.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Authors:  Ted W Johnson; Paul F Richardson; Simon Bailey; Alexei Brooun; Benjamin J Burke; Michael R Collins; J Jean Cui; Judith G Deal; Ya-Li Deng; Dac Dinh; Lars D Engstrom; Mingying He; Jacqui Hoffman; Robert L Hoffman; Qinhua Huang; Robert S Kania; John C Kath; Hieu Lam; Justine L Lam; Phuong T Le; Laura Lingardo; Wei Liu; Michele McTigue; Cynthia L Palmer; Neal W Sach; Tod Smeal; Graham L Smith; Albert E Stewart; Sergei Timofeevski; Huichun Zhu; Jinjiang Zhu; Helen Y Zou; Martin P Edwards
Journal:  J Med Chem       Date:  2014-06-03       Impact factor: 7.446

7.  Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

Authors:  Curtis R Chong; Magda Bahcall; Marzia Capelletti; Takayuki Kosaka; Dalia Ercan; Taebo Sim; Lynette M Sholl; Mizuki Nishino; Bruce E Johnson; Nathanael S Gray; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

8.  Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Authors:  Michaël Duruisseaux; Benjamin Besse; Jacques Cadranel; Maurice Pérol; Bertrand Mennecier; Laurence Bigay-Game; Renaud Descourt; Eric Dansin; Clarisse Audigier-Valette; Lionel Moreau; José Hureaux; Remi Veillon; Josiane Otto; Anne Madroszyk-Flandin; Alexis Cortot; François Guichard; Pascaline Boudou-Rouquette; Alexandra Langlais; Pascale Missy; Franck Morin; Denis Moro-Sibilot
Journal:  Oncotarget       Date:  2017-03-28

9.  A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Authors:  Alexander Drilon; Romel Somwar; Jacob P Wagner; Nadeem A Vellore; Christopher A Eide; Matthew S Zabriskie; Maria E Arcila; Jaclyn F Hechtman; Lu Wang; Roger S Smith; Mark G Kris; Gregory J Riely; Brian J Druker; Thomas O'Hare; Marc Ladanyi; Monika A Davare
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531

10.  Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Authors:  Alice T Shaw; Enriqueta Felip; Todd M Bauer; Benjamin Besse; Alejandro Navarro; Sophie Postel-Vinay; Justin F Gainor; Melissa Johnson; Jorg Dietrich; Leonard P James; Jill S Clancy; Joseph Chen; Jean-François Martini; Antonello Abbattista; Benjamin J Solomon
Journal:  Lancet Oncol       Date:  2017-10-23       Impact factor: 41.316
View more
  2 in total

1.  The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain.

Authors:  Manon Defaye; Mircea C Iftinca; Vinicius M Gadotti; Lilian Basso; Nasser S Abdullah; Mélissa Cuménal; Francina Agosti; Ahmed Hassan; Robyn Flynn; Jérémy Martin; Vanessa Soubeyre; Gaetan Poulen; Nicolas Lonjon; Florence Vachiery-Lahaye; Luc Bauchet; Pierre Francois Mery; Emmanuel Bourinet; Gerald W Zamponi; Christophe Altier
Journal:  J Clin Invest       Date:  2022-06-15       Impact factor: 19.456

Review 2.  Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Authors:  Zuan-Fu Lim; Patrick C Ma
Journal:  J Hematol Oncol       Date:  2019-12-09       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.